Whitepaper: Risk-Based Quality Management (RBQM)
đź“„ About This Document
Learn how Risk-Based Quality Management (RBQM) can enhance the quality, efficiency, and oversight of clinical trials. This one-pager outlines the key principles of RBQM, its core components, and insights from a case study on SDV in neurodegenerative studies.
đź“Ą Download the full document to explore how RBQM strategies can optimize your clinical projects.
Related
The Hidden Cost of Waiting to Rescue an At-Risk Clinical Trial
How sponsors can recognize material underperformance, diagnose root causes, and select the least disruptive path to recovery. Clinical trials rarely move from “on track” to “in crisis” overnight. Warning signs usually emerge gradually: si...
ESC 2026 Takeaways: Precision Prevention, Smarter Risk Assessment, and the Evolving Future of Cardiovascular Trials
The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
Parkinson’s Is Not One Disease. Why Are We Still Designing Trials as If It Is?
Real-world evidence (RWE) can help neuroscience sponsors account for disease heterogeneity, identify development risks earlier, and build more precise evidence strategies from Day 1.For decades, Parkinson’s disease has often been approached ...